Business Description
Prelude Therapeutics Inc
NAICS : 541714
SIC : 2833
Description
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 161.41 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -74.4 | |||||
| 3-Year EPS without NRI Growth Rate | -74.5 | |||||
| 3-Year FCF Growth Rate | -64.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.69 | |||||
| 9-Day RSI | 63.29 | |||||
| 14-Day RSI | 60.85 | |||||
| 6-1 Month Momentum % | -25.28 | |||||
| 12-1 Month Momentum % | -53.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.52 | |||||
| Quick Ratio | 10.52 | |||||
| Cash Ratio | 10.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -45.41 | |||||
| ROA % | -42.17 | |||||
| ROIC % | -753.43 | |||||
| ROC (Joel Greenblatt) % | -2063.48 | |||||
| ROCE % | -46.44 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.59 | |||||
| Price-to-Tangible-Book | 1.59 | |||||
| EV-to-EBIT | -0.97 | |||||
| EV-to-EBITDA | -0.98 | |||||
| EV-to-FCF | -1.33 | |||||
| Price-to-Net-Current-Asset-Value | 1.71 | |||||
| Price-to-Net-Cash | 1.73 | |||||
| Earnings Yield (Greenblatt) % | -103.09 |
How Prelude Therapeutics Inc (PRLD) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PRLD
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Details
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.55 | ||
| Beta | 0 | ||
| Volatility % | 69.96 | ||
| 14-Day RSI | 60.85 | ||
| 14-Day ATR ($) | 0.561235 | ||
| 20-Day SMA ($) | 6.491 | ||
| 12-1 Month Momentum % | -53.15 | ||
| 52-Week Range ($) | 3.87 - 10.72 | ||
| Shares Outstanding (Mil) | 47.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Prelude Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Prelude Therapeutics Inc Stock Events
| Event | Date | Price($) | Daily Change % | ||
|---|---|---|---|---|---|
| No Event Data | |||||
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||